Knockdown or pharmacological inhibition of integrin-linked kinase (ILK), a protein of the adhesosome complex downstream of the integrins and upregulated in BCR-ABL1T315I+ cells, significantly delayed CML progression in vivo via increased levels of fibronectin, an extracellular matrix protein, in the BMM. Here, ILK is linked to chronic myelogenous leukemia, BCR-ABL1 positive.